Phoenix Powers Global Health at BIO 2025

https://www.investinphoenix.com/news/47

<div class="ExternalClassD4AF2366717E4CDCA1E81AAE6E147DD5">PHOENIX, Ariz. - The City of Phoenix's Community and Economic Development Department (CED) will travel to Boston this month to represent Arizona's capital city at the <a href="https://convention.bio.org/bio-2025" target="_blank">2025 BIO International Convention</a> - one of the world's largest gatherings of leaders in the bioscience and healthcare industries."Phoenix leads the nation as one of the top life science markets, and is a key partner in the global race toward science, health and discoveries advancing personalized medicine and cures," Phoenix Mayor Kate Gallego said. "Health innovation thrives in our city, from clinical trials and research to medical talent to development leading the future of health engineering with the new ASU Health downtown. I am proud to champion the biosciences and healthcare advances delivering the promise of a better quality of life for people everywhere. I encourage attendees to learn more and meet with our team at BIO." The convention, taking place June 16-19, brings together more than 20,000 global executives, researchers, investors, and policymakers to shape the future of biotechnology and medical breakthroughs. CED staff will showcase Phoenix's dominating bioscience ecosystem, including the Phoenix Bioscience Core (PBC), leading research institutions, and a diverse, skilled workforce fueling innovation.CED staff will engage in high-level meetings with international companies considering expansion, promote Phoenix's competitive business environment, and amplify stories of homegrown success. Their efforts are part of a broader strategy to position Phoenix as a destination for innovation and investment.Stephen Albert Johnston, Co-Founder and CEO of Calviri, said: "Calviri's goal is to end cancer - first in dogs, then people. Our first product toward these goals, a diagnostic to detect cancer early in dogs, will be available in August 2025." "Translational Sciences, Inc. (TS), which is based at the Phoenix Bioscience Core campus, is excited to report significant progress in the development of its first-in-class biologics that address unmet needs in patients with cardiovascular disease and stroke. TS is actively enrolling patients in two Phase 2 clinical trials at 65 sites across the U.S., to investigate the safety and efficacy of TS23, a first-in-class monoclonal antibody for safely dissolving blood clots," Guy L. Reed, M.D., M.S., Founder and Chief Scientific Officer, said. “Phoenix is a big part of how we continue to deliver advanced microarrays and microfluidic devices used in next-generation diagnostic products at scale. Being positioned close to our biggest market makes this site strategically important - and a key part of how we support our customers both locally and internationally," Edward Wilkinson, VP and General Manager of SCHOTT MINIFAB, said.SCHOTT MINIFAB is a global leader in contract design, development, and manufacturing for life science research and diagnostic consumables."At Castle Biosciences, our goal is to be at the forefront of precision medicine through our portfolio of innovative molecular tests designed to transform how clinicians and patients approach cancer care," Derek Maetzold, President and CEO, said. "The advanced technologies being used at our Phoenix laboratory, along with our broader research efforts, enable us to help provide clinicians and patients with critical insights based on a patient's individual, unique biology. These insights can help inform more personalized treatment pathway decisions, that may contribute to improved outcomes for patients with skin cancers, Barrett's esophagus and uveal melanoma." Phoenix's leaders are poised to make a significant impact at the BIO conference. Among them, Christine Mackay, the City's Community and Economic Development Director, will participate in a panel titled "The Next Frontier: How Stories Can Unlock the Power of Biotech," scheduled for June 18. This session, part of the convention's Storytelling Stage, will explore how compelling narratives can bridge the gap between complex scientific advancements and public understanding, enhancing trust and engagement in biotechnology. "BIO International is where the future of health is on display. and Phoenix's community of trailblazers is actively impacting that future," Mackay said. "We're showcasing not just our infrastructure, but the talent, research and bold ideas that are making Phoenix a serious contender in health innovation." To schedule a meeting with the Phoenix Business Development team, or to learn more about Phoenix's bioscience hubs, visit <a href="/industries/bioscience-healthcare" target="_blank">PHXisBIO.com</a>. To schedule onsite media interviews at BIO International, or to schedule media interviews in advance of the trip, please contact:Athena Sanchez, Communications Manager City of Phoenix Community and Economic Development Department Call/text: 602-621-0507 <a href="mailto:athena.sanchez@phoenix.gov">Athena.Sanchez@phoenix.gov</a> </div>

Biological scientific image

https://www.investinphoenix.com/Lists/News/Attachments/47/BIO_830038211.jpeg

6/9/2025 10:59:07 PM